Journal of Medicinal Chemistry · 2011 · 489 citations · 55 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryLead OptimizationLigand-based DesignPotency OptimizationReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsAnticancer ActivityFibroblast Growth Factor Receptor SignalingKinase Inhibitor Library DesignSelective Tyrosine Kinase InhibitorsSmall Molecule Tyrosine Kinase InhibitorsTherapeutic Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitor Therapy
A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.
55
WHAT IF: A molecular modeling and drug design program
Gert Vriend · Journal of Molecular Graphics · 1990 · 3.5K citations